Granted Patent
B2
US 12,714,744 · App. 17/736,452 · Granted Aug 25, 2026
Coronavirus and influenza compositions and methods for using them
View Patent ↗
Loading inventors, assignments & file history…
Assignments (3)
SECURITY INTEREST
Recorded Feb 25, 2026
From: NOVAVAX, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 074976/0089 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 29, 2023
From: PATEL, NITA; ZHOU, BIN; GUEBRE-XABIER, MIMI; TIAN, JING-HUI; PORTNOFF, ALYSE D.; MASSARE, MICHAEL J.; SHINDE, VIVEK; FRIES, LOUIS; SMITH, GALE
To: NOVAVAX, INC.
Reel/Frame 065700/0878 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 25, 2023
From: PATEL, NITA; ZHOU, BIN; GUEBRE-XABIER, MIMI; TIAN, JING-HUI; PORTNOFF, ALYSE D.; MASSARE, MICHAEL J.; SHINDE, VIVEK; FRIES, LOUIS; SMITH, GALE
To: NOVAVAX, INC.
Reel/Frame 065335/0600 →
Continuity (5)
Provisional Application
63332537
· Apr 19, 2022
Provisional Application
63255685
· Oct 14, 2021
Provisional Application
63193356
· May 26, 2021
Provisional Application
63184727
· May 5, 2021
References Cited (288)
US 4900549A
· De Vries et al.
· 1990
[cited by applicant]
US 5057540A
· Kensil et al.
· 1991
[cited by applicant]
US 5149650A
· Wertz et al.
· 1992
[cited by applicant]
US 5620690A
· Kersten et al.
· 1997
[cited by applicant]
US 6231859B1
· Kensil
· 2001
[cited by applicant]
US 6245532B1
· Smith et al.
· 2001
[cited by applicant]
US 6352697B1
· Cox et al.
· 2002
[cited by applicant]
US 6428807B1
· Macfarlan et al.
· 2002
[cited by applicant]
US 6524584B2
· Kensil
· 2003
[cited by applicant]
US 6558670B1
· Friede et al.
· 2003
[cited by applicant]
US 6846489B1
· Garcon et al.
· 2005
[cited by applicant]
US 7776343B1
· Cox et al.
· 2010
[cited by applicant]
US 8173141B2
· Cox et al.
· 2012
[cited by applicant]
US 8541003B2
· Anderson et al.
· 2013
[cited by applicant]
US 8563002B2
· Baudoux et al.
· 2013
[cited by applicant]
US 8715692B2
· Pushko et al.
· 2014
[cited by applicant]
US 8821881B2
· Morein et al.
· 2014
[cited by applicant]
US 9675685B2
· Pushko et al.
· 2017
[cited by applicant]
US 9708373B2
· Garcia-Sastre et al.
· 2017
[cited by applicant]
US 20040028698A1
· Colau et al.
· 2004
[cited by applicant]
US 20050142148A1
· Fouchier et al.
· 2005
[cited by applicant]
US 20060121065A1
· Morein et al.
· 2006
[cited by applicant]
US 20060171917A1
· Campbell et al.
· 2006
[cited by applicant]
US 20100239671A1
· Edelman et al.
· 2010
[cited by applicant]
US 20120107353A1
· Morein et al.
· 2012
[cited by applicant]
US 20130122032A1
· Smith et al.
· 2013
[cited by applicant]
US 20140227309A1
· Smith et al.
· 2014
[cited by applicant]
US 20140335049A1
· Morein et al.
· 2014
[cited by applicant]
US 20150202283A1
· Steff et al.
· 2015
[cited by applicant]
US 20150306207A1
· Smith et al.
· 2015
[cited by applicant]
US 20150335730A1
· Smith et al.
· 2015
[cited by applicant]
US 20160184427A1
· Morein et al.
· 2016
[cited by applicant]
US 20180369368A1
· Morein et al.
· 2018
[cited by applicant]
US 20200215189A1
· Morein et al.
· 2020
[cited by applicant]
US 20200345840A1
· Morein et al.
· 2020
[cited by applicant]
AU 2003245220B2
· 2009
[cited by applicant]
AU 2014100888A4
· 2014
[cited by applicant]
AU 2022270082A1
· 2023
[cited by applicant]
BR 112016006122B1
· 2023
[cited by examiner]
BR 1120230230357A2
· 2024
[cited by applicant]
CA 2491457C
· 2012
[cited by applicant]
CA 3217591A1
· 2022
[cited by applicant]
CN 1472332A
· 2004
[cited by applicant]
CN 101090711A
· 2007
[cited by applicant]
CN 102107003A
· 2011
[cited by applicant]
CN 112480217A
· 2021
[cited by examiner]
CN 112546211A
· 2021
[cited by examiner]
CN 113185613A
· 2021
[cited by examiner]
EP 0109942A2
· 1984
[cited by applicant]
EP 0242380B1
· 1991
[cited by applicant]
EP 0180564B1
· 1991
[cited by applicant]
EP 0436620B1
· 1994
[cited by applicant]
EP 0362279B1
· 1995
[cited by applicant]
EP 0889736B1
· 2003
[cited by applicant]
EP 1539231B1
· 2009
[cited by applicant]
EP 4333885A1
· 2024
[cited by applicant]
IL 308180A
· 2024
[cited by applicant]
JP 2014504634A
· 2014
[cited by applicant]
JP 2023568063
· 2022
[cited by applicant]
JP 2023533772A
· 2023
[cited by applicant]
MX a2023013081
· 2022
[cited by applicant]
RU 2403063C1
· 2010
[cited by applicant]
RU 2685185C2
· 2019
[cited by applicant]
TW 202308685A
· 2023
[cited by applicant]
WO WO8809336A1
· 1988
[cited by applicant]
WO WO9003184A1
· 1990
[cited by applicant]
WO WO9611711A1
· 1996
[cited by applicant]
WO WO9730728A1
· 1997
[cited by applicant]
WO WO9836772A1
· 1998
[cited by applicant]
WO WO20010066137A1
· 2001
[cited by applicant]
WO WO2004004762A1
· 2004
[cited by applicant]
WO WO2004085633A1
· 2004
[cited by applicant]
WO WO2005002620A1
· 2005
[cited by applicant]
WO WO2005080417A2
· 2005
[cited by applicant]
WO WO2007149490A1
· 2007
[cited by applicant]
WO WO2009081285A2
· 2009
[cited by applicant]
WO WO2010077717A1
· 2010
[cited by applicant]
WO WO2010138193A2
· 2010
[cited by applicant]
WO WO2012061815A2
· 2012
[cited by applicant]
WO WO2013049342A1
· 2013
[cited by applicant]
WO WO2014024024A1
· 2014
[cited by applicant]
WO WO2014124423A1
· 2014
[cited by applicant]
WO WO2014174018A1
· 2014
[cited by applicant]
WO WO2015042373A1
· 2015
[cited by applicant]
WO WO2017041100A2
· 2017
[cited by applicant]
WO WO2018081318A1
· 2018
[cited by applicant]
WO WO2018170347A1
· 2018
[cited by applicant]
WO WO2019183063A1
· 2019
[cited by applicant]
WO WO2021154763A1
· 2021
[cited by applicant]
WO WO2021154812A1
· 2021
[cited by applicant]
WO WO2021155323A1
· 2021
[cited by applicant]
WO WO2021211760A1
· 2021
[cited by examiner]
WO WO2022046634
· 2022
[cited by applicant]
Peacock, T.P., Goldhill, D.H., Zhou, J. et al. The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets. Nat Microbiol 6, 899-909 (2021). (Year: 2021).
[cited by examiner]
Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, Mclellan JS. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. Mar. 13, 2020;367(6483):1260-1263. (Year: 2020).
[cited by examiner]
Hsieh et al 2020. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science. Sep. 18, 2020;369(6510):1501-1505. (Year: 2020).
[cited by examiner]
McCallum M, Walls AC, Bowen JE, Corti D, Veesler D. Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation. Nat Struct Mol Biol. Oct. 2020;27(10):942-949. (Year: 202…
[cited by examiner]
Kirchdoerfer et al 2016. Pre-fusion structure of a human coronavirus spike protein. Nature 531, 118-121 (2016). (Year: 2016).
[cited by examiner]
Schrader and Torkehagen 2020 (Vaxess Technologies, published on line Sep. 15, 2020, https://www.medigenvac.com/en/news_view.php?id=98) (Year: 2020).
[cited by examiner]
Fox 4 Now 2021 (YouTube, video Combination flu and COVID vaccine possible, video uploaded by Fox 4 Now on Feb. 24, 2021) (Year: 2021).
[cited by examiner]
Sekiya et al 2019. Inactivated whole virus particle vaccine with potent immunogenicity and limited IL-6 induction is ideal for influenza. Vaccine. Apr. 3, 2019;37(15):2158-2166. (Year: 2019).
[cited by examiner]
Massare, M. J., Patel, N., Zhou, B., Maciejewski, S., Flores, R., Guebre-Xabier, M., . . . & Smith, G. (2021). Combination respiratory vaccine containing recombinant SARS-CoV-2 spike and quadrivalent seasonal influenza …
[cited by examiner]
International Search Report and Written Opinion for International Application No. PCT/US2022/027465 dated Aug. 10, 2022, 11 pages.
[cited by applicant]
Massare et al. Combination respiratory vaccine containing recombinant SARS-CoV-2 spike 1-8 and quadrivalent seasonal influenza hemagglutinin nanoparticles with matrix-m adjuvant. BioRxiv. May 5, 2021, pp. 1-27, [online]…
[cited by applicant]
“Safety Evaluation of Certain Food Additives and Contaminants Quillaia Extracts,” WHO Food Additives Series:48, 14 pages (1996).
[cited by applicant]
Ahlberg et al., Global transcriptional response to ISCOM-Matrix adjuvant at the site of administration and in the draining lymph node early after intramuscular injection in pigs, Developmental and Comparative Immunology…
[cited by applicant]
Anonymous, “Novavax to Present at the 2013 Stifel Nicolaus Healthcare Conference,” Reuters, 1 page http://in.reuters.com/article/2013/09/05/idUSnGNX7PTmrq+1d8+GNW20130905 (2013).
[cited by applicant]
Anonymous, “Stifel 2013 Healthcare Conference,” pp. 1-35, http://www.novavax.com/download/file/2013_09_12%20Novavax_Stifel_presentation.pdf (2013).
[cited by applicant]
Barr et al., “ISCOMs and other saponin based adjuvants,” Advanced Drug Delivery Reviews, (1998), 32: 247-271.
[cited by applicant]
Behboudi et al., “Quillaja Saponin Formulations that Stimulate Proinflammatory Cytokines Elicit a Potent Acquired Cell-Mediated Immunity,” Scand. J. Immunol. 50:371-377 (1999).
[cited by applicant]
Bengtsson et al., Matrix-M adjuvant increases immunogenicity of seasonal influenza vaccine for the elderly, manuscript in preparation, pp. 1-27 (2014).
[cited by applicant]
Boulter, et al., Evaluation of recombinant sporozoite antigen SPAG-1 as a vaccine candidate against Theileria annulata by the use of different delivery systems, Tropical Medicine and International Health, vol. 4, pp. A7…
[cited by applicant]
Brandenburg et al., Respiratory Syncytial Virus Specific Serum Antibodies in Infants Under Six Months of Age: Limited Serological Response Upon Infection, J. Med. Virol. 52:97-104 (1997).
[cited by applicant]
Chan et al., “Functional Characterization of Heptad Repeat 1 and 2 Mutants of theSpike Protein of Severe Acute Respiratory Syndrome Coronavirus,” Journal of Virology 3225-3237 (2006).
[cited by applicant]
Chatterjee et al., “The 2019 novel coronavirus disease (COVID-19) pandemic: A review of the current evidence,” Indian J Med Res 151(2-3):147-159 (Year: 2020).
[cited by applicant]
Chen et al., “RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak,” Emerging Microbes & Infections 9(1):313-319 (2019).
[cited by applicant]
Chen, Y. et al., “Emerging coronaviruses: Genome structure, replication, and pathogenesis”; Journal of Medical Virology; (Jan. 22, 2020); vol. 92; issue 4, 7 pages.
[cited by applicant]
Cheng et al., “Use of convalescent plasma therapy in SARS patients in Hong Kong,” Eur. J. Clin. Microbiol. Infect. Dis. 24(1):44-46 (2005).
[cited by applicant]
Citovsky et al., “Fusion of Sendai Virions or Reconstituted Sendai Virus Envelopes with Liposomes or Erythrocyte Membranes Lacking Virus Receptors,” The Journal of Biological Chemistry 260(22)12072-12077 (1985).
[cited by applicant]
Coleman et al., “Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice,” Vaccine 32(26):3169-3174 (2014).
[cited by applicant]
“Committee for Veterinary Medicinal Products, Quillaia Saponins, Summary Report”, The European Agency for the rgJ Evaluation of Medicinal Products, EMEA/MRL/055/95-FINAL, Feb. 1996, pp. 1-2.
[cited by applicant]
Copland et al., “Hydration of lipid films with an aqueous solution of Quil A: a simple method for the preparation of immune-stimulating complexes,” International Journal of Pharmaceutics 196:135-139 (2000).
[cited by applicant]
Coulter, et al., Studies on experimental adjuvanted influenza vaccines: comparison of immune stimulating complexes(Iscoms) and oil-in-water vaccines; Vaccine, vol. 16, No. 11/12, pp. 1243-1253 (1998), Elsevier Science L…
[cited by applicant]
Cox, et al., Development of an Influenza-ISCOM Vaccine, in Vaccine Design (eds. G. Gregoriadis et al.), Springer Science+Business Media, New York (1997), pp. 33-49.
[cited by applicant]
Cox, et al., Evaluation of a virosomal H5N1 vaccine formulated with Maxtrix M adjuvant in phase I clinical trial, Elsevier Ltd, Vaccine, 29, pp. 8049-8059, Aug. 22, 2011.
[cited by applicant]
Cox, et al., Prospects for the Development of New Vaccine Adjuvants, BioDrugs, vol. 12(6), pp. 439-453 (1999), Ad is International Limited.
[cited by applicant]
Creemers et al., “Endoproteolytic Cleavage of Its Propeptide Is a Prerequisite for Efficient Transport of Furin Out of the Endoplasmic Reticulum,” J. Biol. Chem. 270(6):2695-2702 (1995).
[cited by applicant]
Crowe, Jr. “Influence of Maternal Antibodies on Neonatal Immunization against Respiratory Viruses,” Clin. Infect. Dis. 33:1720-1727 (2001).
[cited by applicant]
Database UniProt [Online], “SubName: Full=S Protein {ECO:0000313|EMBL:AGN70973.1},” EBI accesion No. UNIPROT:R9UQ53, Database accession No. R9UQ53 (2013).
[cited by applicant]
Delmas and Laude, “Assembly of Coronavirus Spike Protein into Trimers and Its Role in Epitope Expression,” Journal of Virology 64(11):5367-5375 (1990).
[cited by applicant]
Demana et al., “A comparison of pseudo-ternary diagrams of aqueous mixtures of Quil A, cholesterol and phospholipid prepared by lipid-film hydration and dialysis,” Journal of Pharmacy and Pharmacology 56:573-580 (2004).
[cited by applicant]
Demana et al., “Pseudo-ternary phase diagrams of aqueous mixtures of Quil A, cholesterol and phospholipid prepared by the lipid-film hydration method,” International Journal of Pharmaceutics 270:229-239 (2004).
[cited by applicant]
Demirjian and Levy, “Safety and Efficacy of Neonatal Vaccination,” Eur. J. Immunol. 39(1):36-46 (2009).
[cited by applicant]
Drane et al., “Iscomatrix adjuvant for prophylactic and therapeutic vaccines,” Expert Rev. Vaccines 6:761-772 (2007).
[cited by applicant]
Du et al., “The spike protein of SRS-CpV—a target for vaccine and therapeutic development,” Nat. Rev. Microbiol. 7(3):226-236 (2009).
[cited by applicant]
Du, L., et al., “Identification of a Receptor-Binding Domain in the S Protein of the Novel Human Coronavirus Middle East Respiratory Syndrome Coronavirus as an Essential Target for Vaccine Development,” J. Virol. 87(17)…
[cited by applicant]
Duan, et al., An overview of the novel coronavirus MERS-CoV, Chin J Viral Dis, 3(4):245-249 (2013).
[cited by applicant]
Eckert et al., “Mechanisms of Viral Membrane Fusion and Its Inhibition,” Annual Review of Biochemistry 70:770-810 (2001).
[cited by applicant]
Ekstrom et al., “Iscom and iscom-matrix enhance by intranasal route the IgA responses to OVA and rCTB in local and remote mucosal secretions,” Vaccine 17:2690-2701 (1999).
[cited by applicant]
Ennis et al., “Augmentation of Human Influenza A Virus-Specific Cytotoxic T Lymphocyte Memory by Influenza Vaccine and Adjuvanted Carriers (ISCOMS),” Virology 25:256-261 (1999).
[cited by applicant]
Eyles et al., “Immunodominant Francisella tularensis antigens identified using proteome microarray,” Proteomics 7:2172-2183 (2007).
[cited by applicant]
Follis et al.,“Furin cleavage of the SARS coronavirus spike glycoprotein enhances cell-cell fusion but does not affect virion entry,” Virology 350(2):358-369 (2006).
[cited by applicant]
Fossum et al., Early inflammatory response to the saponin adjuvant Matrix-M in the pig, Veterinary Immunology and Immunopathology, http://dx.doi.org/10.1 016/j.vetimm.2013.07.007 (2013), pp. 1-9, Elsevier B.V.
[cited by applicant]
Genbank Accession No. AAC55970.1, “fusion glycoprotein precursor [Human respiratory syncytial virus]” (1996), 1 page.
[cited by applicant]
Genocea Biosciences, Genocea Reports Positive Initial Phase 1/2A Results for GEN-003, It's Pioneering Therapeutic Vaccine Candidate for the Treatment of Herpes Simplex Virus-2 (HSV-2), at ICAAC 2013, press release, Camb…
[cited by applicant]
Giannos et al., Formulation Stabilization and Disaggregatoin of Bevacizumab, Ranibizumab and Aflibercept in Dilute Solutions, Pharm Res 35:78 (2018), 15 pages.
[cited by applicant]
Gillim-Ross et al., “Emerging Respiratory Viruses: Challenges and Vaccine Strategies,” Clin. Microbiol. Rev. 19(4):614-636 (2006).
[cited by applicant]
Glenn et al., “Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine,” Vaccine. Jan. 7, 2013;31(3):524-532.
[cited by applicant]
Glenn, “Recombinant, Insect Cell-Derived RSV Nanoparticle Vaccine,” Novavax.com, 34 pages (Jul. 4, 2012) https://www.novavax.com/download/file/RSV nanoparticleVaccine-MVADsJuly4(2).pdf.
[cited by applicant]
Gonzalez-Reyes et al., “Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion,” Proc. Natl. Acad. Sci. USA 98(17):9859-9864 (2001).
[cited by applicant]
Gretebeck et al., “Animal models for SARS and MERS coronaviruses,” Virology, 13:123-129 (Year: 2015).
[cited by applicant]
Gruenke et al., “New Insights into the Spring-Loaded Conformational Change of Influenza Virus Hemagglutinin,” Journal of Virology, May 2002, 76:(9) 4456-4466 (2002).
[cited by applicant]
Halsey and Galazka, “The efficacy of DPT and oral poliomyelitis immunization schedules initiated from birth to 12 weeks of age,” Bull. World Health Org. 63(6):1151-1169 (1985).
[cited by applicant]
Higgins et al., “Advances in RSV vaccine research and development—A global agenda,” Vaccine 34:2870-2875 (2016).
[cited by applicant]
Hilgenfeld et al., “From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses,” Antiviral Res. 100(1):286-295 (2013).
[cited by applicant]
Hoffman, M. et al., “Priming Time: How Cellular Proteases Arm Coronavirus Spike Proteins”; Coronavirus Spike Protein: Springer International Publishing AG; (2018); pp. 71-98; DOI: 10.1007/978-3-319-75474-1_4.
[cited by applicant]
Iyer et al., Purified, Proteolytically Mature HIV Type 1 SOSIP gp140 Envelope Trimers, Aids Research and Human Retroviruses 23(6):817-828 (2007).
[cited by applicant]
Jackson et al.,“An mRNA Vaccine against SARS-CoV-2 Preliminary Report,” The New England Journal of Medicine, pp. 1-12 (2020).
[cited by applicant]
Jiang, et al., “A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC”, Journal of Infection (66):464-466 (2013).
[cited by applicant]
Johansson et al., “Iscoms with different quillaja saponin components differ in their immunomodulating activities,” Vaccine 17:2894-2900 (1999).
[cited by applicant]
Kam et al.,“Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro,” Vaccine 25(4):729-740 (2007).
[cited by applicant]
Kanekiyo et al., “Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing HINI antibodies,” Nature 2013, vol. 499 p. 102-108.
[cited by applicant]
Karin Lovgren Bengtsson, Bror Morein & Albert DME Osterhaus (2011) ISCOM technology-based Matrix M adjuvant: success in future vaccines relies on formulation, Expert Review of Vaccines, 10:4, 401-403, DOI: 10.1586/erv.1…
[cited by applicant]
Kensil, Saponins as Vaccine Adjuvants, Critical Reviews in Therapeutic Drug Carrier Systems, vol. 13(1&2), pp. 1-55 (1996), Begell House, Inc.
[cited by applicant]
Kersten et al., On the structure of immune-stimulating saponin-lipid complexes (iscoms) Biochimica et Biophysica Acta, 1062:165-171 (1991).
[cited by applicant]
Kim et al., “Respiratory Syncytial Virus Disease in Infants Despite Prioir Administration of Antigenic Inactivated Vaccine,” Am. J. Epidemil. 89(4):422-434 (1969).
[cited by applicant]
Kirchdoerfer et al., “Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis,” Scientific Reports, pp. 1-11 (2018).
[cited by applicant]
Kleine-Weber et al., Functional analysis of potential cleavage sites in the MERS coronavirus spike protein, Scientific Reports vol. 8, No. 1, article 16597, pp. 1-11 (2018).
[cited by applicant]
Korber et al.,“Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,” Cell 182:1-16 (2020).
[cited by applicant]
Kuroiwa, Y., et al., “Antigen-specific human polyclonal antibodies from hyperimmunized cattle,” Nat. Biotechnol. 27(2):173-181 (2009).
[cited by applicant]
Lavelle et al., “Cholera Toxin Promotes the Induction of Regulatory T Cells Specific for Bystander Antigens by Modulating Dendritic Cell Activation,” Journal of Immunology 171:2384-2392 (2003).
[cited by applicant]
Lee et al., “Recent Advances of Vaccine Adjuvants for Infectious Diseases ,” Immune Network, 51-57 (2015).
[cited by applicant]
Li et al., “Immunogenicity and Protection Efficacy of Monomeric and Trimeric Recombinant SARS Coronavirus Spike Protein Subunit Vaccine Candidates,” Viral Immunology 26(2):126-132 (2013).
[cited by applicant]
Lichtenberg et al., “The Mechanism of Detergent Solubilization of Lipid Bilayers,” Biophysical Journal, vol. 105:289-299 (2013).
[cited by applicant]
Lieberman et al., “Preparation and immunogenic properties of a recombinant West Nile subunit vaccine,” Vaccine 25:414-423 (2007).
[cited by applicant]
Liu et al., “Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV,” Vacci…
[cited by applicant]
Lovgren et al., The Requirement of Lipids for the Formation of Immunostimulating Complexes (Iscoms), Biotechnol. Appl. Biochem. 10:161-172 (1988).
[cited by applicant]
Lovgren-Bengtsson, 6 Preparation and Use of Adjuvants; Methods in Microbiology, vol. 25, pp. 471-502 (1998), Academic Press Ltd.
[cited by applicant]
Lovgren-Bengtsson et al., “4.5 Preparation and Use of Adjuvants,” Methods in Microbiology 32:551-588 (2002).
[cited by applicant]
Lu et al., “Immune responses against severe acute respiratory syndrome coronavirus induced by virus-like particles in mice,” Immunol. 122:496-502 (2007).
[cited by applicant]
Lucy et al., “Structure and Assembly of Macromolecular Lipid Complexes Composed of Globular Micelles,” Journal of Molecular Biology, (1964), 8: 727-748.
[cited by applicant]
Magnusson et al., Immune enhancing properties of the novel Matrix-M adjuvant leads to potentiated immune responses to an influenza vaccine in mice, Vaccine, http://dx.doi.org/10.1 016/j.vaccine.2013.01.039 (2013), pp. 1…
[cited by applicant]
Magnusson et al., Matrix-M adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice, Vaccine vol. 32, pp. 800-808 (2014), Elsevier Ltd.
[cited by applicant]
Makwana et al., “Prefilled Syringes: An Innovation in Parenteral Packaging,” International Journal of Pharmaceutical Investigation 1(4):200-206 (2011).
[cited by applicant]
Matsushita et al., “Triple immunoglobulin gene knockout transchromosomic cattle: bovine lambda cluster deletion and its effect on fully human polyclonal antibody production,” PLOS One 9(3):1-14 (2014).
[cited by applicant]
McKenzie et al., ISCOMATRIX vaccines: Safety in human clinical studies, Human Vaccines, vol. 6, No. 3, pp. 237-246 (2010), Landes BioScience.
[cited by applicant]
Morein et al., “Current status and potential application of ISCOMs in veterinary medicine,” Advanced Drug Delivery Reviews 56:1367-1382 (2004).
[cited by applicant]
Murphy et al., “An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines,” Virus Res. 32:13-26 (1994).
[cited by applicant]
NCT01669512, Adjuvanting Viral Vectored Malaria Vaccines with Matrix M, dated Mar. 9, 2014, pp. 14.
[cited by applicant]
NCT04368988, Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant, dated Apr. 30, 2020, 21 pages.
[cited by applicant]
NCT04533399, A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults, dated Aug. 31, 2020, 18 pages.
[cited by applicant]
NCT04583995, A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom, dated Oct. 12, 2020, 11 pages.
[cited by applicant]
NCT04611802, A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults â%
[cited by applicant]
NCT04834869, COVID-19 Vaccines Safety Tracking (CoVaST), dated Apr. 8, 2021, 11 pages.
[cited by applicant]
NCT04889209, Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines, dated May 17, 2021, 16 pages.
[cited by applicant]
NCT04961541, Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine, dated Jul. 14, 2021, 14 pages.
[cited by applicant]
NCT05029856, Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-COV-2 (COVID-19) Variant in Adults, dated Sep. 1, 2021, 13 pages.
[cited by applicant]
NCT05112848, A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-COV-2 (COVID-19), dated Nov. 9, 2021, 16 pages.
[cited by applicant]
NCT05236491, COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases, dated Feb. 11, 2022, 9 pages.
[cited by applicant]
NCT05249816, Phase 3 Study to Evaluate a Single Booster of the NVX-CoV2373 COVID19 Vaccine in Adults, dated Feb. 22, 2022, 11 pages.
[cited by applicant]
NCT05372588, Phase 3 Booster Study for the SARS-CoV-2 rS Vaccines, dated May 12, 2022, 12 pages.
[cited by applicant]
Nord, “Novel acetylated triterpenoid saponins in a chromatographic fraction from Quilaja saponinaria Molina,” Carb. Res. 329:817-829 (2000).
[cited by applicant]
“Novavax NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial,” Press Release dated Mar. 24, 2020, 3 pages.
[cited by applicant]
NTC04961541, “Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine,” dated Jul. 14, 2021, 14 pages.
[cited by applicant]
Nussbaum et al., “Fusion of influenza Virus particles with liposomes: requirement for cholesterol and virus receptors to allow fusion with and lysis of neutral but not of negatively charged liposomes”,. Journal of Gener…
[cited by applicant]
Ozel et al., “Quaternary Structure of the Immunostimulating Complex (Iscom),” Journal of Ultrastructure and Molecular Structure Research 102:240-248 (1989).
[cited by applicant]
Pallesen et al., “Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen,” PNAS E7348-E7357 (2017).
[cited by applicant]
Parrington et al., “Baculovirus expression of the respiratory syncytial virus fusion protein using Trichoplusia ni insect cells,” Virus Genes 14:63-72 (1997).
[cited by applicant]
Parrish, “Novavax creates MERS-CoV vaccine candidate,” http://vaccinenewsdaily.com/vaccine_development/325407-novavax-creates-mers-cov-vaccine-candidate/ (2013).
[cited by applicant]
Pedersen et al., Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model, Influenza and Other Respiratory Viruses. DOI: 1 0.1111/j.1750-2659.2011.00256.x (2011 ), p…
[cited by applicant]
Pedersen, et al.; T-Helper 1 Cells Elicited by H5N1 Vaccination Predict Seroprotection, Journal of Infectious Disease, 206, pp. 158-166, Jul. 15, 2016.
[cited by applicant]
Poulsen et al., “Limits for Antibody Affinity Maturation and Repetoire Diversification in Hyper vaccinated Humans,” J. Immunol. 187(8):4429-4235 (2011).
[cited by applicant]
Rama et al., “An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization”, V…
[cited by applicant]
Rey, F. A. et al., “Common Features of Enveloped Viruses and Implications for Immunogen Design for Next-Generation Vaccines”; Cell; (Mar. 8, 2018); vol. 172; issue 6.
[cited by applicant]
Rimmelzwaan. et al., A randomized, double blind study in young healthy adults comparing cell mediated and 1 humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines; Vaccine, 2001, vol. 19,…
[cited by applicant]
Ronnberg et al., “Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrix,” Vaccine, vol. 13, No. 14, pp. 1375-1382 (1995).
[cited by applicant]
Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine, Identifier NCT01667341, ClinicalTrials.gov, U.S. National Institutes of Health; available at http://clinicaltrials.gov/ct2/show/NCT01667341 ?term=matrix+m&ra…
[cited by applicant]
Sales and Wang, “Respiratory syncytial virus vaccine: Is it coming?” Paediatr. Child Health 8(10):605-608 (2003).
[cited by applicant]
Sekimukai et al., “Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies…
[cited by applicant]
Shen, X. et al. Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351, N Engl J Med. (Apr. 7, 2021).
[cited by applicant]
Shi et al., “Stabilization of Human Papillomavirus Virus-Like Particles by Non-Ionic Surfactants,” Journal of Pharmaceutical Sciences, 2005, p. 1538-1551.
[cited by applicant]
Shimizu, “Chapter 32. Routes of Administration,” in The Laboratory Mouse, Hans Hedrich and Gillian Bullock, Eds., Elsevier Academic Press, 15 pages (2004).
[cited by applicant]
Shinde et al., “Improved Titers Against Influenza Drift Variants with a Nanoparticle Vaccine,” N Engl Med 378:24 (2018), 3 pages.
[cited by applicant]
Shinde et al, Induction of Broadly Cross-Reactive Immune Responses Against A(H3N2) Viruses: Results of a Phase 2 Trial of a Novel Recombinant Hemagglutinin Saponin-Adjjvanted nanoparticle Influenza Vaccine (“NanoFlu”), …
[cited by applicant]
Siegrist, “Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants,” Vaccine 21:3406-3412 (2003).
[cited by applicant]
Sjolander, et al., ISCOMs: an adjuvant with multiple functions, Journal of Leukocyte Biology, vol. 64, pp. 713-723 (1998).
[cited by applicant]
Sjolander, et al., Uptake and adjuvant activity of orally delivered saponin and ISCOM vaccines, Advanced Drug Delivery Reviews, vol. 34, pp. 321-338 (1998), Elsevier Science B.V.
[cited by applicant]
Skoberne et al., An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in Guinea pigs, J. Virol. 87:3930-3942 (2013).
[cited by applicant]
Smith et al., “Novel hemagglutinin nanoparticle influenza vaccine with Matrix-M adjuvant induces hemagglutination inhibition, neutralizing, and protective responses in ferrets against homologous and drifted A(H3N2) subt…
[cited by applicant]
Song, F., et al., “Middle East Respiratory Syndrome Coronavirus Spike Protein Delivered by Modified Vaccinia Virus Ankara Efficiently Induces Virus-Neutralizing Antibodies,” J. Virol. 87(21):11950-11954 (2013).
[cited by applicant]
Sun et al., “Advances in saponin-based adjuvants,” Vaccine 27:1787-1796 (2009).
[cited by applicant]
Sun et al., “ISCOMs and ISOMATRIX,” Vaccine 27:4388-4401 (2009).
[cited by applicant]
Tekewe et al., A rapid and simple screening method to identify conditions for enhanced stability of modular vaccine candidates, Biochemical Engineering Journal 100:50-58 (2015).
[cited by applicant]
Third Party Observation: Additional Comments in Respect of WO2021154812, Document #11 issued for International Application No. PCT/US2021/015220 on May 27, 2022, 2 pages.
[cited by applicant]
Third Party Observation issued for International Application No. PCT/US2021/015220 on May 27, 2022, 11 pages.
[cited by applicant]
Tian et al., “SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice,” Jun. 29, 2020, 50 pages.
[cited by applicant]
Tian et al., “SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice,” Nature Communications vol. 12, No. 1, Article 372, pp. 1-14 (2021).
[cited by applicant]
Vaarala et al., “Antigenic Differences between AS03 Adjuvanted Influenza A (H1N1) Pandemic Vaccines: Implications for Pandemrix Associated Narcolepsy Risk,” PLOS One, 1-23 (2014).
[cited by applicant]
Van Boheemen et al., “Genomic Characterization of a Newly Discovered Coronavirus Associated with Acute Respiratory Distress Syndrome in Humans,” mBio 3(6):e00473-12, 9 pages (2012).
[cited by applicant]
Van Doremalen N. et al. ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. bioRxiv, 23 pages (2020).
[cited by applicant]
Wald, “A Novel Therapeutic Vaccine (GEN003) for Genital Herpes Reduces HSV-2 Shedding: Initial Results of Clinical Trial GEN003-001,” Presented at Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC …
[cited by applicant]
Wald et al., Novel Therapeutic Vaccine for Genital Herpes Reduces Genital HSV-2 Shedding, in ICAAC 2013, Denver, CO, Sep. 2013, cover page and p. 279, Abstract 183(G).
[cited by applicant]
Walls et al., “Functional Characterization of Heptad Repeat 1 and 2 Mutants of the Spike Protein of Severe Acute Respiratory Syndrome Coronavirus,” Nature 531, 17 pages (2016).
[cited by applicant]
Wang et al., “Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses,” Frontiers in Microbiology, 11:298, 19 pages (Year: 2020).
[cited by applicant]
Wang, “Protein aggregation and its inhibition in biopharmaceutics,” International Journal of Pharmaceutics 289 (2005) 1-30.
[cited by applicant]
Weisshaar et al., “Blocking Respiratory Syncytial Virus Entry: A Story with Twists,” DNA Cell Biol. 34:505-510 (2015).
[cited by applicant]
Whitehead et al., “Recombinant Respiratory Syncytial Virus (RSV) Bearing a Set of Mutations from Cold-Passaged RSV is Attenuated in Chimpanzees,” J. Virol. 72(5):4467-4471 (1998).
[cited by applicant]
Wrapp et al.,“Cryo EM Structure of the 2019 nCoV spike in the Prefusion Conformation,” bioRxiv, posted Feb. 15, 2020 online at https://doi.org/10.1101/2020.02.11.944462, 30 pages.
[cited by applicant]
Wrapp et al.,Cryo EM Structure of the 2019 nCoV spike in the Prefusion Conformation Science 10.1126/science.abb2507 (2020), 9 pages.
[cited by applicant]
Wu et al., “Active 1918 pandemic flu viral neuraminidase has distinct N-glycan profile and is resistant to trypsin digestion,” Biochemical and Biophysical Research, 2009, vol. 379. p. 749-753.
[cited by applicant]
Yeh, “Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital,” J. Antimicrob. Chemother. 56(5):919-922 (2005).
[cited by applicant]
European Patent Office, “Extended European Search Report”, App. No. 22799423.3, Feb. 25, 2025, 9 pgs.
[cited by applicant]
Taiwan Patent Office, “Notice of First Office Action”, App. No. TW 111116974, Jan. 23, 2026, 15 pgs. (with English translation).
[cited by applicant]
Russian Patent Office, “Office Action” App. No. 2023131792, Oct. 23, 2025, 22 pgs. (with English 1 translation).
[cited by applicant]
C. Nozaki, “Current Status and Challenges of Vaccines”, Faculty of Health Science, Kumamoto Health Science University, 2016, vol. 76, No. 1, pp. 4-10 (18 pp. with English translation).
[cited by applicant]
Japan Patent Office, “Office Action”, App. No. 2023-568063, Apr. 13, 2026, 7 pgs. (with English translation).
[cited by applicant]